JD-5037 is primarily researched for its potential therapeutic applications, particularly in the field of metabolic disorders and endocannabinoid system modulation. It acts as a selective antagonist of the cannabinoid receptor 1 (CB1), which is implicated in regulating appetite, energy balance, and lipid metabolism. Studies suggest its use in managing obesity and related metabolic conditions by reducing food intake and improving insulin sensitivity. Additionally, JD-5037 is being explored for its role in treating liver fibrosis and non-alcoholic fatty liver disease (NAFLD), as it may help mitigate inflammation and fat accumulation in the liver. Its ability to modulate the endocannabinoid system without crossing the blood-brain barrier makes it a promising candidate for reducing systemic side effects often associated with CB1 antagonists. Ongoing research continues to evaluate its efficacy and safety in these applications.